niacin and Atheroma
niacin has been researched along with Atheroma in 10 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0." | 6.78 | Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013) |
| "Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0." | 2.78 | Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013) |
| "Dalcetrapib has been well tolerated at the 600-mg dose." | 2.48 | An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. ( Arsenault, BJ; Brodeur, MR; Rhainds, D; Tardif, JC, 2012) |
| " In conclusion, these data suggest that long-term administration of nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions, which are independent of its lipid-modifying actions." | 1.37 | Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities. ( Albrecht, C; Bea, F; Blessing, E; Buttler, A; Holzhäuser, E; Katus, HA; Preusch, MR; Zhou, Q, 2011) |
Research
Studies (10)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chai, JT | 1 |
| Digby, JE | 1 |
| Ruparelia, N | 1 |
| Jefferson, A | 1 |
| Handa, A | 1 |
| Choudhury, RP | 1 |
| Sibley, CT | 1 |
| Vavere, AL | 1 |
| Gottlieb, I | 1 |
| Cox, C | 1 |
| Matheson, M | 1 |
| Spooner, A | 1 |
| Godoy, G | 1 |
| Fernandes, V | 1 |
| Wasserman, BA | 1 |
| Bluemke, DA | 1 |
| Lima, JA | 1 |
| Lim, GB | 1 |
| Ylä-Herttuala, S | 1 |
| Bentzon, JF | 1 |
| Daemen, M | 1 |
| Falk, E | 1 |
| Garcia-Garcia, HM | 1 |
| Herrmann, J | 1 |
| Hoefer, I | 1 |
| Jauhiainen, S | 1 |
| Jukema, JW | 1 |
| Krams, R | 1 |
| Kwak, BR | 1 |
| Marx, N | 1 |
| Naruszewicz, M | 1 |
| Newby, A | 1 |
| Pasterkamp, G | 1 |
| Serruys, PW | 1 |
| Waltenberger, J | 1 |
| Weber, C | 1 |
| Tokgözoglu, L | 1 |
| Kuge, Y | 1 |
| Takai, N | 1 |
| Ogawa, Y | 1 |
| Temma, T | 1 |
| Zhao, Y | 1 |
| Nishigori, K | 1 |
| Ishino, S | 1 |
| Kamihashi, J | 1 |
| Kiyono, Y | 1 |
| Shiomi, M | 1 |
| Saji, H | 1 |
| Holzhäuser, E | 1 |
| Albrecht, C | 1 |
| Zhou, Q | 1 |
| Buttler, A | 1 |
| Preusch, MR | 1 |
| Blessing, E | 1 |
| Katus, HA | 1 |
| Bea, F | 1 |
| Rhainds, D | 1 |
| Arsenault, BJ | 1 |
| Brodeur, MR | 1 |
| Tardif, JC | 1 |
| Strack, AM | 1 |
| Carballo-Jane, E | 1 |
| Wang, SP | 1 |
| Xue, J | 1 |
| Ping, X | 1 |
| McNamara, LA | 1 |
| Thankappan, A | 1 |
| Price, O | 1 |
| Wolff, M | 1 |
| Wu, TJ | 1 |
| Kawka, D | 1 |
| Mariano, M | 1 |
| Burton, C | 1 |
| Chang, CH | 1 |
| Chen, J | 1 |
| Menke, J | 1 |
| Luell, S | 1 |
| Zycband, EI | 1 |
| Tong, X | 1 |
| Raubertas, R | 1 |
| Sparrow, CP | 1 |
| Hubbard, B | 1 |
| Woods, J | 1 |
| O'Neill, G | 1 |
| Waters, MG | 1 |
| Sitlani, A | 1 |
| Phan, BA | 1 |
| Muñoz, L | 1 |
| Shadzi, P | 1 |
| Isquith, D | 1 |
| Triller, M | 1 |
| Brown, BG | 1 |
| Zhao, XQ | 1 |
| HUNTER, JD | 1 |
| WONG, LC | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The RIGHT Study: Risk Stratification With Image Guidance of HMG Coa Reductase Inhibitor Therapy[NCT01212900] | Phase 4 | 230 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy[NCT00715273] | Phase 4 | 217 participants (Actual) | Interventional | 2001-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change in Mean of Wall Volume of Internal Carotid Arteries
Wall volume of internal carotid arteries was measured using magnetic resonance imaging. Participants will undergo 2D and 3D carotid MRI using a 3 Tesla scanner and surface carotid coils. Participants with mild or no atherosclerosis, defined as the lowest tertile of wall volume, will have statin therapy adjusted to a target range of 100-130 mg/dL. Participants in the middle tertile will receive statin therapy adjusted to achieve a target LDL 70-100 mg/dL. Participants with the most severe atherosclerosis will receive statin therapy to an LDL target between 40 and 70 mg/dL. Participants in the Standard arm will have lipid sub-fraction targets determined according to estimated 10 year cardiovascular risk, as per standard NCEP guidelines. (NCT01212900)
Timeframe: 24 months
| Intervention | Other - mm^3 ( cubic millimeter ) (Mean) |
|---|---|
| Imaging | -3.52 |
| Standard | -5.91 |
Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
| Intervention | mm^3/year (Mean) |
|---|---|
| 1 - Single Therapy Group | -4.6 |
| 2 - Double Therapy Group | -15.1 |
| 3 - Triple Therapy Group | -9.4 |
Annualized LRNC and Wall Volume Changes in Carotid Plaque Composition, as Assessed by MRI
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
| Intervention | percentage change/year (Mean) | |
|---|---|---|
| LRNC change | Wall Volume change | |
| 1 - Single Therapy Group | -1.6 | -0.6 |
| 2 - Double Therapy Group | -3.6 | -1.4 |
| 3 - Triple Therapy Group | -2.8 | -1.2 |
Composite of Cardiovascular Endpoints: Number of Participants With Cardiovascular Disease Death, Non-fatal Heart Attack, Stroke, and Worsening Ischemia Requiring Medical Interventions
Any cardiovascular events such as death from any cause, nonfatal myocardial infarction, stroke, and revascularization procedures (PCI or CABG) due to unstable ischemia will be recorded and verified. (NCT00715273)
Timeframe: Measured at Years 3, 4, and 5
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Composite Measured at Year 3 | Composite Measured at Year 4 (cumulative) | Composite Measured at Year 5 (cumulative) | |
| 1 - Single Therapy Group | 6 | 7 | 9 |
| 2 - Double Therapy Group | 6 | 11 | 11 |
| 3 - Triple Therapy Group | 7 | 9 | 9 |
Reviews
1 review available for niacin and Atheroma
| Article | Year |
|---|---|
An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Prote | 2012 |
Trials
2 trials available for niacin and Atheroma
| Article | Year |
|---|---|
MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study.
Topics: Aged; Carotid Artery Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydro | 2013 |
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment
Topics: Blood Glucose; Carotid Stenosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary | 2013 |
Other Studies
7 other studies available for niacin and Atheroma
| Article | Year |
|---|---|
Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.
Topics: ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Bin | 2013 |
Atherosclerosis: Addition of niacin to optimal statin therapy does not affect plaque regression.
Topics: Carotid Artery Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Re | 2013 |
Stabilization of atherosclerotic plaques: an update.
Topics: Antihypertensive Agents; Apolipoprotein B-100; Blood Platelets; CCR5 Receptor Antagonists; Chemokine | 2013 |
Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques.
Topics: Animals; Antibodies, Monoclonal; Humans; Immunoglobulin G; Male; Matrix Metalloproteinase 14; Molecu | 2010 |
Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities.
Topics: Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Apolipoproteins E; Brachiocephalic Trunk; Female | 2011 |
Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis.
Topics: Animals; Aorta; Apolipoproteins E; Cholesterol; Drug Interactions; Endpoint Determination; Female; G | 2013 |
Nicotinic acid effect on cockerels. Cholesterol and atheroma lesions.
Topics: Animals; Arteriosclerosis; Chickens; Cholesterol; Humans; Male; Niacin; Nicotinic Acids; Plaque, Ath | 1961 |